Loading…
Saroja Pharma Industries India (SAROJA)₹40.00+3.09%Specialty Chemicals
In the Mar 2026 quarter (standalone), Saroja Pharma Industries India reported sales of ₹31.60 Cr, down 10.3% from Mar 2025, and net profit of ₹1.03 Cr, up 49.3% year on year. For the year to Mar 2026, sales were ₹70.54 Cr and net profit ₹1.61 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 23.82 | 21.21 | 19.44 | 18.85 | 35.24 | 38.92 | 31.60 |
| Expenses | 22.20 | 19.89 | 18.13 | 17.52 | 33.23 | 37.30 | 28.95 |
| Operating Profit | 1.46 | 1.18 | 1.20 | 1.22 | 1.78 | 1.38 | 2.44 |
| OPM % | 6.1% | 5.6% | 6.2% | 6.5% | 5.1% | 3.5% | 7.8% |
| Other Income | 0.00 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.65 | 0.84 | 0.61 | 0.70 | 0.73 | 0.54 | 0.94 |
| Depreciation | 0.06 | 0.03 | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 |
| Profit before tax | 0.73 | 0.68 | 0.50 | 0.46 | 0.98 | 0.77 | 1.44 |
| Tax % | 27.1% | 27.6% | 27.4% | 27.7% | 29.3% | 26.9% | 28.3% |
| Net Profit | 0.53 | 0.49 | 0.37 | 0.33 | 0.69 | 0.56 | 1.03 |
| EPS (Rs) | 1.83 | 1.23 | 0.94 | 0.84 | 1.73 | 1.41 | 2.58 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 36.81 | 55.88 | 50.37 | 40.83 | 53.92 | 70.54 |
| Expenses | 35.27 | 53.40 | 47.30 | 38.02 | 50.78 | 66.22 |
| Operating Profit | 1.31 | 2.11 | 2.73 | 2.57 | 2.79 | 3.82 |
| OPM % | 3.6% | 3.8% | 5.4% | 6.3% | 5.2% | 5.4% |
| Other Income | 0.10 | 0.33 | 0.17 | 0.20 | 0.20 | 0.00 |
| Interest | 0.32 | 0.79 | 1.33 | 1.44 | 1.42 | 1.47 |
| Depreciation | 0.01 | 0.04 | 0.06 | 0.08 | 0.10 | 0.10 |
| Profit before tax | 1.03 | 1.56 | 1.48 | 1.20 | 1.44 | 2.23 |
| Tax % | 28.8% | 28.1% | 28.9% | 27.3% | 29.0% | 27.7% |
| Net Profit | 0.72 | 1.13 | 1.05 | 0.87 | 1.02 | 1.61 |
| EPS (Rs) | 729.41 | 50.39 | 3.60 | 2.18 | 2.55 | 4.02 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.02 | 0.24 | 2.94 | 4.02 | 4.03 | 4.03 |
| Reserves | 0.92 | 3.79 | 2.14 | 10.60 | 11.64 | 13.26 |
| Borrowings | 3.03 | 6.14 | 10.18 | 5.74 | 9.49 | 14.45 |
| Other Liabilities | 4.25 | 5.31 | 6.04 | 6.18 | 14.36 | 10.00 |
| Total Liabilities | 8.22 | 15.48 | 21.30 | 26.54 | 39.52 | 41.74 |
| Fixed Assets | 0.10 | 0.35 | 2.23 | 2.52 | 2.52 | 2.19 |
| CWIP | 0.00 | 0.00 | 1.78 | 6.12 | 8.62 | 20.35 |
| Investments | 0.00 | 0.03 | 0.13 | 0.19 | 0.33 | 0.53 |
| Other Assets | 8.12 | 15.10 | 17.16 | 17.71 | 28.05 | 18.67 |
| Inventories | 0.65 | 0.46 | 3.86 | 0.39 | 0.09 | 0.85 |
| Trade receivables | 7.23 | 14.01 | 11.13 | 16.28 | 26.63 | 17.32 |
| Cash & equivalents | 0.00 | 0.25 | 0.35 | 0.31 | 0.32 | 0.33 |
| Total Assets | 8.22 | 15.48 | 21.30 | 26.54 | 39.52 | 41.74 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | −1.04 | −3.66 | 2.18 | 1.01 | 1.14 | 7.42 |
| Cash from investing activity | −0.06 | −0.35 | −4.84 | −4.77 | −2.71 | −11.72 |
| Cash from financing activity | 1.02 | 4.25 | 2.72 | 3.69 | 1.55 | 4.23 |
| Net cash flow | −0.08 | 0.27 | 0.11 | −0.05 | 0.02 | 0.02 |
| Capex | 0.04 | 0.29 | 3.72 | 0.38 | 0.10 | 11.69 |
| Free cash flow | −1.09 | −3.96 | −1.53 | −3.69 | −1.44 | −4.04 |
| CFO / OP % | −58.0% | −154.1% | 96.0% | 53.0% | 56.0% | 212.0% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 72 | 92 | 81 | 146 | 181 | 90 |
| Inventory days | 7 | 3 | 31 | 4 | 1 | 5 |
| Days payable | 45 | 39 | 47 | 57 | 103 | 48 |
| Cash conversion cycle | 35 | 58 | 66 | 93 | 80 | 47 |
| Working capital days | 21 | 32 | 16 | 71 | 29 | 5 |
| ROCE % | — | 33.5% | 22.1% | 14.9% | 12.6% | 13.0% |
For the Mar 2026 quarter, Saroja Pharma Industries India reported sales of ₹31.60 Cr, down 10.3% year on year and net profit of ₹1.03 Cr, up 49.3% year on year. The operating margin was 7.8%.
Saroja Pharma Industries India's sales for the year to Mar 2026 were ₹70.54 Cr.
Net profit for the year to Mar 2026 was ₹1.61 Cr. Earnings per share over the same trailing period were ₹4.02.
Saroja Pharma Industries India reported borrowings of ₹14.45 Cr at Mar 2026, against cash and equivalents of ₹0.33 Cr.
Cash from operations was ₹7.42 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹4.04 Cr.